Business Wire

Lumen Partners With UK's top PT Harry Jameson to Raise Awareness on Metabolic Health

Share

Lumen, the creators of the world's first metabolism measurement device through the breath, have teamed up with the UK's top personal trainer, Harry Jameson, to raise awareness on metabolic health for March Metabolism Awareness Month.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210309005629/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Lumen metabolism tracking device and personalised nutrition (Photo: Lumen)

Harry is available for expert commentary on training to improve your metabolism.

"Having the ability to move between energy sources (fat and carbohydrates) is extremely important. It is a measure of your metabolic health and I’ve been working hard over the past two months to improve mine.

Using Lumen to track whether my diet, fasting or even training is pushing my metabolism in the right direction has been both fascinating from a coaches perspective and incredibly insightful from a user/customer perspective. I love how lumen keeps me both accountable and consistent with my behaviours and getting personalised nutrition plans really helps take a mental load off my shoulders in my busy schedule," says personal trainer Jameson.

Lumen and Jameson are also working together to emphasise the importance of metabolic health in combating metabolic syndrome. In the UK, 1 in 3 adults over the age of 50 will suffer from metabolic disease which is a combination of diabetes, high blood pressure (hypertension) and obesity.

The power to move away from metabolic disease by training your metabolism to switch efficiently between carbs and fats as a fuel source is a term called metabolic flexibility.

"If we feed and train our metabolism, we can process our food more efficiently - you may be able to eat a slice of pie and use it for energy faster if you have a good metabolism. We are merely training our body to use fuel sources properly- an innate mechanism. There's really no need to crash diet , if we take care of our metabolism everything else follows", says PHD in nutrition and founder of Lumen, Michal Mor.

According to research data obtained by 1 million metabolism measurements through the Lumen device, users are able to:

  • Lose an average of 0.5 kg or 1.5 pounds of weight per week on a consistent basis
  • Improve their metabolic flexibility by 66%
  • Improve fasting windows to 12 hours daily
  • Increase their daily movement by 1000 steps

Research also (Calcada et al, Gormsen et al) finds that metabolic flexibility has a profound role in assessing a person's long-term health. People with good metabolic flexibility:

  • Are at lower risk of developing obesity, diabetes and metabolic disorders.
  • Are in a better position to gain muscle and perform better during workouts;
  • Find it easier to lose weight and maintain it

Lumen is the only device in the world to measure your metabolism through the breath and track your metabolic health to prevent diseases born out of poor nutrition.

Based on the traditional RER test which was once available only in hospitals or clinics, is accessible to anyone and anywhere for the first time-revolutionizing the way we approach weight loss, fitness and healthy nutrition decision making.

Through the co2 in your breath, Lumen measures your metabolism and provides an insight into whether you're burning fats or carbs in less than a minute.

Scientific Validation

Lumen can provide numerous insights about the metabolism of an individual, as well as valuable scientific data to increase knowledge of metabolic flexibility and nutrition. In a study conducted by San Francisco State University, Lumen has been validated to meet the gold standard for metabolic measurement.

Availability

The Lumen device is available at Lumen.me, currently priced at £299.

The device comes equipped with a travel case, charging dock, USB-C Cable, and Premium Customer Support. Users can download the app for free on the Apple App Store and on Google Play.

For media: images, video and fact sheet can be found in the press kit here.

About Lumen

Lumen helps people improve their health and fitness through technology on the forefront of personalized nutrition and metabolism. Conceived and designed by twin sisters, physiology PhDs and Ironman winners, Lumen harnesses the power of our breath to measure metabolism, which is closely linked to weight, fitness and personal health. The Lumen device measures metabolism in a single breath, in less than a minute, which previously was only possible through an hour-long lab test. Available at Lumen.me, Lumen devices ship globally, with the app available on the Apple App Store and Google Play. Lumen is headquartered in Israel, with offices in the United States.

[1] Sources: The role of low-grade inflammation and metabolic flexibility in aging and nutritional modulation thereof: A systems biology approach. Available via: https://www.sciencedirect.com/science/article/pii/S0047637414000050. Last accessed 5 May 2020.

[2] Source: Estradiol acutely inhibits whole body lipid oxidation and attenuates lipolysis in subcutaneous adipose tissue: a randomized, placebo-controlled study in postmenopausal women. Available via:https://eje.bioscientifica.com/view/journals/eje/167/4/543.xml

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media contact: Kyla Blumenfeld, press@lumen.me

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Visa Launches Stablecoin Settlement in the United States, Marking a Breakthrough for Stablecoin Integration16.12.2025 14:00:00 EET | Press release

Visa Inc. (V) today announced the launch of USDC settlement in the United States, marking a major milestone in the company’s stablecoin settlement pilot program and strategy to modernize its settlement layer underpinning global commerce. For the first time, U.S. issuer and acquirer partners can settle with Visa in Circle’s USDC, a fully reserved, dollar-denominated stablecoin. With USDC settlement, issuers can benefit from faster funds movement over blockchains, seven‑day availability and enhanced operational resilience across weekends and holidays - without any change to the consumer card experience. Initial banking participants include Cross River Bank and Lead Bank, which have started settling with Visa in USDC over the Solana blockchain. Broader availability in the U.S. is planned through 2026. Additionally, Visa is a design partner for Arc, a new Layer 1 blockchain developed by Circle (currently in public testnet). Arc’s purpose-built design offers the performance and scalability

Dompé Doses First Patients in Europe and US in Phase 3 Study of Isocyclosporin for Atopic Keratoconjunctivitis16.12.2025 14:00:00 EET | Press release

Dompé, a leading biopharmaceutical company with operations in Italy and the U.S., announced the first patients have been enrolled in a Phase 3 study of Isocyclosporin for the treatment of atopic keratoconjunctivitis (AKC). Isocyclosporin is a dual inhibitor of transient receptor potential (TRP) cation channel, mucolipin subfamily, member 2 (TRPML2) and calcineurin, key regulators of immune and inflammatory response in chronic inflammatory eye diseases. The Phase 3 trial is a multicenter, randomized, double-masked study comparing isocyclosporin against vehicle control in improving ocular signs and symptoms after six weeks of treatment. “This milestone underscores Dompé’s commitment to groundbreaking science with the potential for life-changing patient impact,” said Marcello Allegretti, Chief Scientific Officer at Dompé. “The dual mechanism of isocyclosporin has the potential to redefine treatment and quality of life for patients living with poorly managed AKC. It also marks an important

Volante Technologies Customers Successfully Navigate Critical Regulatory Deadlines for EU SEPA Instant and Global SWIFT Cross-Border Payments16.12.2025 11:00:00 EET | Press release

Volante Technologies, the global leader in Payments as a Service (PaaS), today announced it has successfully upgraded its clients to meet the latest SEPA Instant Payments Regulation (IPR) and SWIFT SRG 2025 mandate, which came into effect October 9th and November 22nd, 2025, respectively. This announcement follows the major FedISO upgrade in July, which shifted trillions of dollars in payments to the new ISO 20022 messaging format. SEPA IPR is a significant European milestone, requiring payments to be made within 10 seconds and at any time of day, throughout the year. Adoption was mandatory and Eurozone banks were compelled to meet strict deadlines, with January 9th, 2025 the deadline for receiving incoming instant payments and October 9th the deadline for sending outgoing instant payments. The latest deadline impacted more than 700 banks across Europe, with non-compliance penalties reaching at least 10% of annual net turnover. SWIFT SRG 2025 is another seismic update, representing the

TreeFrog Therapeutics Announces Changes to Executive Committee With the Arrival of Mark Rothera as Chief Executive Officer & Board Member to Spearhead Next Phase of Growth16.12.2025 10:05:00 EET | Press release

TreeFrog Therapeutics, a French biotech focused on bringing regenerative medicine to millions through their proprietary cell technology, C-Stem™ is delighted to announce the appointment of skilled biotech leader, Mark Rothera, as Chief Executive Officer and Board member. He succeeds Frédéric Desdouits, who is stepping down after five years in the role. In the new leadership configuration, co-founders Kévin Alessandri and Maxime Feyeux will transition from daily operations to focus on their roles on the Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215145193/en/ Mark Rothera, CEO TreeFrog Therapeutics Elsy Boglioli, Chair of the Board of TreeFrog Therapeutics, commented “On behalf of the Board, we are delighted to welcome Mark to TreeFrog. His 30+ years of biopharma leadership, including most recently, three biotech CEO roles in gene therapy and biologics, will be invaluable as we advance our Parkinson’s and liver

RoslinCT and Ayrmid Ltd. Announce Expansion of Strategic Partnership to Manufacture Omisirge ® (omidubicel-onlv) for Second FDA-Approved Indication in Severe Aplastic Anemia (SAA)16.12.2025 10:00:00 EET | Press release

Ayrmid Ltd., the parent company of Gamida Cell Inc., a pioneering cell therapy company transforming cells into powerful therapeutics, and RoslinCT, a global leader in cell and gene therapy contract development and manufacturing, today announced the expansion of their strategic partnership to include the execution of a commercial supply agreement to support production of Omisirge® (omidubicel-onlv). Following positive clinical trial results, Omisirge® has received FDA approval for a second indication, broadening its use in the treatment of hematology patients. Under the commercial supply agreement, RoslinCT will complete technology transfer and support commercial manufacturing of Omisirge® for this additional indication at its state-of-the-art cGMP cell therapy manufacturing facility in Hopkinton, MA. “We are excited to expand our collaboration with RoslinCT to add US manufacturing as Omisirge® moves into its next phase with the recent FDA approval for patients suffering from severe apl

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye